
<mods xmlns="http://www.loc.gov/mods/v3" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-4.xsd">
    
    <titleInfo>
        <title>Antiretroviral prophylaxis: a defining moment in HIV control</title>
    </titleInfo>
    <name type="personal" ID="ssa16">
        <namePart type="family">Abdool Karim</namePart>
        <namePart type="given">Salim</namePart>
        <role>
            <roleTerm type="text">author</roleTerm>
        </role>
        <affiliation>Columbia University. Epidemiology</affiliation>
    </name>
    <name type="personal" ID="qa4">
        <namePart type="family">Abdool Karim</namePart>
        <namePart type="given">Quarraisha</namePart>
        <role>
            <roleTerm type="text">author</roleTerm>
        </role>
        <affiliation>Columbia University. Epidemiology</affiliation>
    </name>
    <name type="corporate">
        <namePart>Columbia University. Epidemiology</namePart>
        <role>
            <roleTerm type="text">originator</roleTerm>
        </role>
    </name>
    <typeOfResource>text</typeOfResource>
    <genre>Articles</genre>
    
    <originInfo>
        <dateIssued encoding="w3cdtf" keyDate="yes">2011</dateIssued>
    </originInfo>
    
    <language>
        <languageTerm type="text">English</languageTerm>
    </language>
    <abstract>A defining moment in the global AIDS response has been reached. The discourse is no longer about HIV prevention or HIV treatment; it is now about HIV control through the implementation of antiretrovirals as key components of combination interventions. Barely a year ago, visions of HIV control would have been considered far-fetched. The impetus for this change in mindset, which has been building since the XVIII International AIDS Conference in Vienna last year, emanates from the compelling evidence that antiretroviral drugs prevent HIV infection in the general heterosexual population, which is released this week and presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Rome by the Partners PrEP and Botswana TDF2 trials.</abstract>
    <subject>
        <topic>Virology</topic>
    </subject>
    <subject>
        <topic>Epidemiology</topic>
    </subject>
    <relatedItem type="host">
        <titleInfo>
            <title>Lancet</title>
        </titleInfo>
        <part>
            <detail type="volume">
                <number>378</number>
            </detail>
            <detail type="issue">
                <number>9809</number>
            </detail>
            <extent unit="page">
                <start>e23</start>
                <end>e25</end>
            </extent>
            <date>2011</date>
        </part>
        <identifier type="doi">http://dx.doi.org/10.1016/S0140-6736(11)61136-7</identifier>
    </relatedItem>
    <identifier type="hdl">http://hdl.handle.net/10022/AC:P:12482</identifier>
    
    <location>
        <physicalLocation authority="marcorg">NNC</physicalLocation>
    </location>
    
    <recordInfo>
        <recordContentSource authority="marcorg">NNC</recordContentSource>
        <recordCreationDate encoding="w3cdtf">2012-02-07 12:56:52 -0500</recordCreationDate>
        <recordChangeDate encoding="w3cdtf">2012-07-31 14:12:26 -0400</recordChangeDate>
        <recordIdentifier>6484</recordIdentifier>
        <languageOfCataloging>
            <languageTerm authority="iso639-2b">eng</languageTerm>
        </languageOfCataloging>
    </recordInfo>
    
</mods>
